Locations:
Search IconSearch

News & Insights

19-NEU-152-Russman-650×450

The State of Cerebrovascular Care as Seen by AAN’s Incoming Stroke Section Vice Chair

Dr. Andrew Russman shares priorities, new developments to watch for

19-NEU-122_CQD_650x450_hero
February 19, 2019/Geriatrics

PET Ligand GE-180 Cleared for Testing to Assess Inflammation in Neurodegenerative Disease

Cleveland Clinic IND application is first approved in Parkinson’s and Alzheimer’s

18-NEU-5778-Walter-DBS-650×450
November 20, 2018/Neurosciences/News & Insights

What’s New and Emerging in Deep Brain Stimulation? Q&A with Dr. Benjamin Walter

New director of our DBS program talks new applications, tech advancements and more

18-NEU-4988-Retouched-Rothner-Erenberg-Lifetime-Achievement_650x450

The Long View of Child Neurology from Drs. Gerald Erenberg and David Rothner

Founders of our pediatric neurology program reflect on the past and future

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

How many fingers am I holding up?
September 4, 2018/Neurosciences/News & Insights

Mild Head Injury in Children: Limit Imaging to High-Risk Cases

New CDC guideline issued on diagnosing and managing pediatric mTBI

18-NEU-5506-Phase-3-Alzheimers-Trials-650×450
August 27, 2018/Geriatrics

Analysis of Alzheimer’s Drug Pipeline Reveals Slow Progress, a Few Bright Spots

Third annual report shows shift toward prevention studies, disease-modifying therapies

18-NEU-4778_Parkinsons-Brain-650×450

What Does It Really Mean to Be a Parkinson’s Disease Center of Excellence?

One center’s perspective on its designation from the Parkinson’s Foundation

18-NEU-917-CSC-Stroke-Center-650×450

A Blueprint for Zero RFIs in a Comprehensive Stroke Center Survey

Q&A with Cleveland Clinic’s stroke program leader on secrets of success

18-NEU-981-Ahmed-Migraine-650×450

CGRP Inhibitors for Migraine Prevention: What Prescribers Need to Know

New monoclonal antibody is first agent to address migraine prevention head-on

BackPage 3 of 4Next

Advertisement

Ad